Boulle Therapeutics identifies, invests in, and supports the development of early, seed stage innovations that have the potential to save lives and improve the quality of life for large numbers of people.
Investments
Trained Therapeutix Discovery – TTxD uses proprietary advanced bioengineering technologies to treat the most detrimental of human diseases by taking control of the innate immune response. The team are at the forefront of advanced research to address some of the most recalcitrant and debilitating diseases, including cancer and serious infection. In November 2020 a preclinical study published in Cell and co-authored by TTxD’s scientific founders demonstrated how trained immunity can be therapeutically exploited to help fight cancers.
Publications
Trained Immunity and Atherosclerosis
Therapeutic Targeting of Trained Immunity
Defining trained immunity
Transplantation paper
